MediPal Holdings (7459) Q4 2026 earnings summary

Executive summary

• Achieved record-high net sales of ¥3,817.3 billion for FY2025, with all business segments posting growth despite a volatile environment.

• Ordinary profit rose 16.0% to ¥75.7 billion, while operating profit declined by 4.4% to ¥53.2 billion due to higher costs and investments.

• Profit attributable to owners of parent increased 5.6% to ¥42.5 billion; comprehensive income surged 42.6% to ¥66.8 billion.

• Advanced growth investments, executed shareholder return policies, and completed strategic acquisitions and partnerships, including Cygni Holdings and a joint development agreement with JCR Pharmaceuticals.

• Major initiatives included overseas expansion, new drug development, and group integration efforts.

Financial highlights

• Net sales: ¥3,817.3 billion, up 4.0% year-over-year.

• Ordinary profit: ¥75.7 billion, up 16.0% year-over-year.

• Profit attributable to owners of parent: ¥42.5 billion, up 5.6% year-over-year.

• Adjusted operating profit: ¥59.5 billion, up 0.9% year-over-year.

• Gross profit margin: 6.84% in FY2025; SG&A expenses: ¥207.8 billion, up 3.8% year-over-year.

Outlook and guidance

• FY2026 forecast: Net sales ¥3,944.0 billion (+3.3%), operating profit ¥55.0 billion (+3.4%).

• Ordinary profit and profit attributable to owners of parent expected to decline due to absence of extraordinary gains.

• Annual dividend per share projected to increase to ¥68.

• Forecast does not include impact of making PALTAC a wholly owned subsidiary; positive effects on net income, EPS, and ROE anticipated.

• Continued investment in digital transformation and sustainable logistics.